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Bacillus Calmette-Guerin (BCG),4 an attenuated strain of Mycobacterium bovis,
was developed as a vaccine against human tuberculosis by Calmette and Guerin at
the Pasteur Institute in 1908. BCG has recently regained the spotlight in completely
different roles, that of an immunological adjuvant and "'antitumor" agent. Investiga-
tions with this agent in the immunotherapy of cancer have met with variable success
in different animal systems and with limited success in a small number of human
trials. The majority of this work has been done on an empirical basis using tumor re-
gression or animal survival as the end point. The effects of BCG on the immune
response are multifaceted, and a clearer understanding of its mechanism of action
may lead to a more rational basis for its use, not only in cancer immunotherapy, but
in other immunologic applications.
Antitumor Effects
In the nearly two decades since BCG was first reported to increase the re-
sistance of rats and mice to a variety of transplantable tumors (7, 17, 60), a large
number of experiments has been performed in an attempt to elucidate the
mechanism of resistance induced by this agent. In guinea pigs, concomitant intra-
dermal administration of BCG and living tumor cells or injection of BCG into small
established tumor nodules resulted in the inhibition of tumor growth and the produc-
tion of systemic immunity to the tumor (68-70). Close contact between the tumor
cells and BCG was necessary, and the induced immunity was tumor specific. This
systemic resistance could not be induced by other common methods of immuniza-
tion, such as injection of killed tumor cells or excision of the primary tumor. The
efficacy of BCG-tumor vaccines or ofintratumoral injections of BCG was more vari-
able in producing tumor regression in mice. Even in those systems where tumor
growth was inhibited, the development of systemic immunity was inconsistent (4, 40,
53).
BCG therapy has also been associated with negative effects, including clinical de-
terioration associated with the appearance of serum blocking factors (40) and hyper-
sensitivity reactions to BCG occasionally resulting in death (38). Increased tumor
growth has occurred after BCG injection or sensitization to purified protein deriva-
tive (PPD) of Mycobacterium tuberculosis (50, 52). BCG-tumor cell mixtures can
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either enhance or reduce artificial experimental pulmonary "metastasis" depending
on the antigenicity of the tumors (1). Established solid tumors may be enhanced by
the systemic administration of BCG, while leukemias are either inhibited or un-
affected (36).
The predominant cell types involved in BCG-mediated augmentation of immunity
to solid tumors are lymphocytes and monocytes (18, 19, 48). The site of inhibition is
characterized by a localized inflammatory response with intense mononuclear in-
filtration, leading to a granuloma. Although the inflammatory response to BCG may
be necessary for the expression of tumor resistance, it may not be sufficient, since
other inflammatory agents do not possess similar effectiveness and may even ac-
celerate tumor growth (19).
Early investigators attributed the effects of BCG to a stimulation of the reticuloen-
dothelial system (RES) and an augmentation of the immune response (2, 6). The evi-
dence presented above suggested that the mechanism of the antitumor activity of
locally administered BCG is a two-step phenomenon involving the specific recogni-
tion of bacterial antigens by the host and then a granulomatous reaction which non-
specifically destroys the tumor cells (an "innocent bystander" effect). Subsequent
development of specific immunity might be due to an increased number of activated
lymphocytes by tumor antigens. While this hypothesis may be valid for solid tumors,
there is a large body of information suggesting that the antitumor effect of BCG is
more than simply the result of the local granulomatous response to BCG antigens.
Administration of BCG can inhibit the induction of tumors by a variety of oncogenic
agents, and mice treated systemically with BCG and subsequently injected with
syngeneic leukemia L1210 show an increased survival time (35). Repeated BCG in-
jections prolong the survival of AKR mice, which normally develop a spontaneous
leukemia (59). Pretreatment of mice with the methanol-insoluble fraction of BCG
(methanol extract residue (MER)), which can mimic most of the adjuvant effects of
the whole organism, reduced the incidence of leukemia following inoculation with
radiation leukemia virus (20). Unfortunately, immunological correlates are generally
not available for these survival studies.
Recent studies have shown that macrophages may play an important role as an
effector cell in allograft resistance, and they may also be important in the resistant
state induced by BCG. Macrophages nonspecifically activated in vitro and in vivo by
a variety of substances including BCG are able to recognize and destroy a variety of
neoplastic cells (10, 22-24, 26) but with a few exceptions (39) demonstrate little or no
cytopathic effect on nontransformed fibroblast lines. In general, early passages of
embryo cells, which showed little contact inhibition, were susceptible to killing by ac-
tivated macrophages. Later passages were minimally affected (10, 26). BCG-
activated adherent peritoneal cells are cytotoxic to tumor lines, while peritoneal exu-
date cells induced by starch, mineral oil, or thioglycollate are not tumoricidal (10).
This is an in vitro correlate of the earlier observations that activation of macrophages
or induction of an inflammatory response may be necessary but is not sufficient for
the expression of the tumoricidal effects of BCG. It is also of interest to note that the
BCG-activated macrophages are' apparently able to discriminate between neo-
antigens of tumors and allo- and xenoantigens on normal cells.
The possible mechanisms underlying the action of BCG against tumors may be
illuminated by the results of immunological studies with that agent in other systems.
This seems to be a valid approach because tumor immunology is not a discipline with
unique principles or circumstances but simply a branch of general immunology.
Thus, information relating to allograft rejection, other varieties of cell-mediated im-
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munity, or even antibody synthesis may well be applicable to immunity against tu-
mors. In addition, recent technological advances in the measurement ofimmunity in
vitro have allowed the conclusions drawn from studies on the survival of animals to
be reexamined on a more sophisticated level.
Effects on Cell-Mediated Immunity
BCG is widely used as an immunizing agent against tuberculosis. Although the
precise mechanisms of immunity to tuberculosis are not known, BCG is presumed to
protect by virtue of a specific antimycobacterial immune response evoked in the vac-
cinated subject (34). In addition, however, alveolar macrophages from rabbits in-
jected with BCG have an increased ability to inhibit nonspecifically the growth of
intracellular organisms, with an accompanying increase in the content of lysosomal
hydrolases (32). Nonspecific resistance (cytotoxicity) to unrelated bacteria can also
be induced in macrophages from animals immunized with Mycobacterium tubercu-
losis, as well as with Listeria monocytogenes or Brucella abortus. The rate of onset
and strength of resistance is dependent upon the vaccinating dose of BCG. Non-
specific killing is dependent upon development of a delayed sensitivity reaction to
BCG. However, heat-killed organisms alone are ineffective in the induction of non-
specific cytotoxicity of microorganisms. This requires the persistence of the inducing
mycobacteria, either through chronic infection with living bacteria or injection of
killed organisms in complete Freund's adjuvant (53). Protection against M. tubercu-
losis infection can be conferred with BCG cell walls attached to oil droplets or a com-
bination of a peptidoglycolipid cell wall skeleton plus a lipid component (52). Mice
inoculated with BCG have an increased rate of clearance of Escherichia coli en-
dotoxin and carbon particles by macrophages of the reticuloendothelial sysfem (28).
BCG-infected animals also clear Salmonella enteriditis more rapidly than control
animals, and they catabolize denatured albumin more rapidly. Not all ofthe underly-
ing immunological mechanisms of nonspecific antimicrobial immunity are under-
stood, since BCG-activated alveolar macrophages have an enhanced ability to kill L.
monocytogenes but not Yersinia tularensis (46). This indicates that, although acti-
vated macrophages demonstrate an increased resistance to a variety of intracellular
organisms ranging from bacteria to viruses, the scope of the nonspecific resistance is
incomplete.
The adjuvant (helper) effect of an active tuberculous infection on cell-mediated im-
munity was first noted by Dienes and Schoenheit, who noted that increased delayed
hypersensitivity reactions (DHR) to egg albumin and timothy pollen could be induced
by injection of the antigen into a tuberculous lesion (12). BCG or its derivatives can
potentiate cell-mediated immunity to protein antigens (41), to haptens conjugated to
normally nonimmunogenic carrier molecules (30), and to poorly immunogenic tumor
lines (21). The wax D fractions from several human types of M. tuberculosis, when
injected together with a protein antigen in a water-in-oil emulsion, could mimic the
adjuvant effect of the whole killed mycobacteria, including the production ofcorneal
hypersensitivity (64). Wax D fractions of several bovine strains of mycobacteria,
including BCG, were not active. The difference appeared to be the presence of a pep-
tide moiety in the human wax D which was absent from the wax D fractions of bo-
vine, as well as the inactive wax D fractions from avian and saprophytic strains ofM.
tuberculosis (62, 64).
Another manifestation of cell-mediated immunity, which can be profoundly
affected by BCG or MER administration, is the rejection of skin grafts (2, 51, 55, 60,
71). The survival of dispersed syngeneic or allogeneic spleen cells in vivo, as
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measured by their ability to synthesize antibodies, is not affected by prior treatment
of recipient mice with BCG. In contrast, BCG markedly decreases the survival of
solid spleen allografts and isografts (8). The initial take of grafts is not influenced by
BCG pretreatment, and it has been suggested that an effect on the proliferation of
immunocompetent lymphocytes after their recognition of antigen is of most im-
portance. Accelerated rejection would result from a more rapid sensitization and an
expanded pool of reactive cells. Accelerated rejection of syngeneic male to female
tail skin grafts was produced when BCG was administered 21 or 28 days before graft-
ing, but treatment with BCG 36 and 7 days before grafting resulted in a prolonged
skin graft survival (71). The accelerated rejection but not the prolongation was ob-
served with allogeneic skin grafts. Nonspecific stimulation of the reticuloendothelial
system was not the major mode of action, since the twice-immunized mice had a
more pronounced increase in reticuloendothelial phagocytic activity than singly im-
munized animals. In addition, the maximal resistance to isografts induced by MER
administration occurs after reticuloendothelial activity has returned to normal, and
splenectomy between BCG administration and skin grafting abolishes the ac-
celerated rejection (2).
BCG pretreatment in vivo significantly increased spleen cell-mediated cytotoxicity
of suboptimally immunized Swiss mice to allogeneic L1210, as measured in vitro.
Interestingly, the administration of BCG alone produced "pseudoimmune" spleen
cells with a high level of cytotoxicity towards L1210 (43). The pseudoimmune cells
were not contained in the glass-adherent population and are probably not typical
macrophages. However, they are found in thymus-deprived mice and are not thymus-
dependent (T) lymphocytes either (Kinder and Mitchell, unpublished data). MER
pretreatment increased the cytotoxic efficacy of lymphocytes from specifically im-
munized donors, and the heightened effect could be transferred passively in this sys-
tem by both lymphoid cells and macrophages (30). MER pretreatment increased the
numbers of cells forming rosettes with sheep erythrocytes in normal and immunized
spleens. Both cells bearing the thymus-specific 0 antigen and those without were
increased (61). The stimulatory effects of BCG and its derivative, MER, are most
marked in animals given small immunizing doses of antigen, and the elevated levels
ofimmunity are generally maintained for several weeks.
Effects on Antibody Synthesis
Humoral antibody synthesis is increased in a variety of systems by BCG treatment
(42, 50, 54, 56). An active tuberculous infection enhances antibody formation to egg
albumin and timothy pollen injected into the lesion (12). BCG pretreatment
increased DNA synthesis in lymph node cells, and there was a good correlation
between increased cell proliferation and the adjuvant effect for both antibody
response and the development of DHR to sheep red blood cells (42). This is in agree-
ment with the correlation between the increased antibody levels after injection of egg
albumin with the wax D fraction of M. tuberculosis and a proliferation of plasma cell
elements in the lymph nodes, spleen, and liver (63).
The work done by Yashphe and her collaborators indicated that MER either
directly or indirectly increased the number of cells which is capable or responding to
an antigenic stimulus (66, 67). MER pretreatment also appears to expand and/or
make more efficient the memory cell pool as well as the antibody-forming cell pool
(61). There is some evidence that some of MER's activity may be at the stage of
antigen processing by macrophages (61). As with the effects on DHR, the MER
adjuvancy for antibody production is more pronounced at low antigen doses or with
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weaker antigenic materials. Unfortunately, the effects ofadjuvant administration are
not easily predictable, since MER pretreatment in guinea pigs could selectively favor
humoral antibody formation or delayed hypersensitivity to hapten-protein con-
jugates, depending on the preciseconditions ofimmunization (61).
Very few adjuvants, other than those directly mitogenic for antibody-forming cell
precursors ("bursa"-dependent lymphocytes, B-cells), appear to exert their effects
by a direct action on B-cells. There is no direct evidence at this time that BCG or its
derivatives are B-cell mitogens. In fact, since other adjuvants require the presence of
specific T-cells to be effective, it is likely that BCG and MER also may enhance anti-
body synthesis by stimulating T-cells to produce soluble factors that stimulate B-
cells (37).
Reversal ofImmunosuppression
Perhaps one of the most interesting and potentially exploitable effects of BCG or
MER is their ability to reverse or protect against the immunosuppressive effects of
various agents. MER largely or completely reversed the immunosuppressive effects
of antithymocyte serum on the circulating antibody response to sheep red blood cells,
whether the MER was given before or after the antithymocyte serum treatment. In
addition, MER markedly protected against the depressive effects of cortisone
acetate on the appearance of rosette-forming cells after immunization with sheep red
cells (61). The immunosuppressive effect of antilymphocyte serum on the immuniza-
tion against allogeneic cells, as measured by the cytotoxic activity of spleen cells
against 5'Cr-labeled target cells, was similarly affected (29).
BCG pretreatment increased the number of plaque-forming cells directed against
sheep red cells and could partially protect against or reverse the immunosuppressive
effect of methylcholanthrene (57). The combination of BCG and methylcholanthrene
resulted in approximately the same number of plaque-forming cells as in the im-
munized controls. BCG can also confer long-lasting protection against the immuno-
suppressive effects of cytarabine (46). Spleen cell-mediated cytotoxicity to allogeneic
leukemia L1210 was decreased by cytarabine alone, but was the same as in im-
munized controls in the group given both BCG and cytarabine. Treatment with BCG
after chemotherapy caused a transient, but significant, reversal of the immunosup-
pression (46). The effector cell population elicited by BCG in this protective action
appears to be a non-thymus-dependent, nonadherent phagocytic cell, probably of the
monocytic cell series.
BCG pretreatment was apparently able to protect against the immunosuppressive
effects of cyclophosphamide, since mice could be made resistant to tumor induction
by a murine sarcoma virus (MSV-M) or could be immunized against challenge by a
MSV-induced tumor even in the face of cyclophosphamide chemotherapy (25, 27).
These effects may be due in part to the induction of interferon production in addition
to the nonspecific stimulatory effects on the immune response (16). The therapeutic
benefit from high toxic doses of cyclophosphamide against syngeneic L1210 leukemia
could be increased by subsequent treatment with BCG (35). The increased efficacy of
combined therapy in this system was attributed to a myeloprotective property of
BCG, since BCG can stimulate bone marrow macrophage colony production but may
well be due to reversal of immunosuppression, too (65). However, in contrast to the
work with the MSV system, BCG pretreatment increased the number of drug-
related deaths following high-dose cyclophosphamide treatment.
A similar reversal of an immunosuppressed state was seen in the antigen-
antibody-induced suppression of macrophage receptors for cytophilic antibody (44).
287288 MURAHATA AND MITCHELL
This suppression could be prevented or reversed by theinjection ofBCG organisms 5
days before or after the suppressive treatment (Mitchell and Mokyr, unpublished
data). Since "suppressor" T-cells appear to be involved in the inhibition
phenomenon (13), it remains to be seen whether the protection and reversal effected
by BCG is mediated through T-cells or is a direct effect on the macrophage
membrane. Direct membrane effects may play a role in the resistance of spleen cells
to immunosuppression by antilymphocyte serum, since isolated cells treated with
MER in vivo were more resistant to the in vitro killing by antilymphocyte serum and
complement (29).
OtherEffects ofBCG on Lymphoid Cells
Another index ofimmunological reactivity is the ability oflymphocytes to respond
to mitogens. Prior administration of BCG has been reported to increase the response
of monkey lymphocytes to the T-cell mitogen, phytohemagglutinin (11), and MER
enhanced the spleen cell response to the B-cell mitogen lipopolysaccharide (LPS) and
of lymph node cells to both LPS and concanavalin A, another T-cell mitogen (14).
However, we have found that BCG can decrease the responsiveness to mitogens of
mouse spleen cells (43, 46). Although the baseline incorporation of [3H]thymidine
was increased tenfold in spleens from BCG-treated mice (43), the subsequent
response to phytohemagglutinin, concanavalin A, and lipopolysaccharide was re-
duced below the response ofnormal spleen cells.
Spleen cells or thymocytes are stimulated to produce DNA when treated with
BCG in vitro. The in vitro stimulation ofthymocytes has an absolute requirement for
macrophages acting in the "afferent" arm ofimmunization (45). Further evidence for
the ability of BCG to promote intercellular cooperation during an immune response
can be found in studies on the recently described lymphocyte-activating factor (15,
43). Adherent spleen cells from BCG immunized mice produced more of the factor
than normal cells. Production of lymphocyte-activating factor by adherent spleen
cells could also be enhanced by in vitro stimulation by BCG, and this effect was
further amplified by the presence of nonadherent spleen cells, suggesting a mutual
stimulation of macrophages and lymphocytes (45). The production of this mediator
from MER-treated peritoneal cells was also increased (14). Our current presumption
is that lymphocyte-activating factor is at least one substance produced by
macrophages in response to adjuvants such as BCG. These substances may expand
and activate populations of T-cells and may thus help to explain the potency of
adjuvants in increasing the responsiveness of immunocompetent cells to an antigen
introduced into the system.
Regardless oftheir future use in immunotherapy, BCG and its derivatives can play
an important role as prototypes in the study ofadjuvancy. Recent advances in obtain-
ing purified cell populations and in tissue culture techniques make it possible to
dissect their actions in stimulating humoral and cell-mediated immunity more com-
pletely. The nature of cell-to-cell interactions in immunity may be better elucidated
through such studies, providing information that goes well beyond the immediate
field of"applied immunology."
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